

Allogeneic transplantation is a curing treatment for patients with therapy related myelodysplastic syndrome despite higher-risk features




266 patients with diagnosis of MDS who received alloHCT



Analysis of clinical characteristics and outcomes



Next generation sequencing of 72 genes



5-year overall survival	49.9%	53.9%	p=0.61
Intermediate-2/High IPSS	59.7%	43.7%	p=0.003
High-risk karyotypes	61.2%	30.7%	p<0.01



t-MDS

30%

mutations in TP53

48%

mutations in high-risk genes (EZH2, ETV6, RUNX1, ASXL1)



No impact

- overall survival
- relapse-free survival